Is This the Best Time to Buy HEXO (TSX:HEXO) Stock?

HEXO had a rough 2019. Will 2020 be better?

| More on:
question marks written reminders tickets

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The meltdown in the stock prices of marijuana companies in the second half of 2020 wiped out billions of dollars in market capitalization, resulting in difficulties for industry players seeking to secure new funding.

Issuing stock isn’t advisable when the chips are down, and big investors with deep pockets are taking a step back to see how things shake out in the coming months.

A recent bounce in the share prices of the sector’s key stocks, however, is attracting new interest from retail investors and contrarians who are wondering whether this might be a good opportunity to add cannabis stocks to their portfolios.

Let’s take a look at HEXO (TSX:HEXO)(NYSE:HEXO) to see if it deserves to be on your buy list.

Wild ride

HEXO traded for $8.50 per share right before the launch of the recreational cannabis market in Canada last October.

Unfortunately, the rollout didn’t go well, with supply shortages and distribution headaches quickly souring the mood and investors bailed out of the sector amid the disappointment. A broad-based equities sell-off also didn’t help.

At the December 2019 low, HEXO was around $4.30 per share. A new rally in in the first part of 2019 took the stock to $10.50 at the end of April, but things turned ugly for HEXO in the following months.

What happened?

HEXO provided a very optimistic view on its fiscal 2020 revenue target when it announced the purchase of Newstrike Brands in March.

The deal increased the number of provincial supply agreements to eight and HEXO said it was targeting $400 million in revenue by the middle of the 2020 business year.

The company reiterated the guidance in June and said its fiscal Q4 results, which ended July 31, would show roughly $26 million in revenue.

On October 10, the company dropped a bomb. HEXO abandoned its rosy revenue forecast for the 2020 year and warned that its upcoming Q4 report would be much worse than anticipated.

When the final Q4 numbers came out on October 29, net revenue was just $15.4 million and the company said it expected fiscal Q1 revenue in 2020 to be $14-18 million.

In addition, HEXO cut 200 jobs in an effort to protect cash flow. The company suspended operations at its Niagara facility and at 200,000 square feet of its Gatineau site. The firm also announced $70 million in new convertible debentures that will carry an 8% interest rate.

On the surface the new funding might be viewed as a vote of confidence, but the money was provided by company insiders, including the CEO and four directors. This might suggest the business is having trouble finding new sources of cash.

To make matters worse, HEXO revealed it had discovered product had been grown in unlicensed areas at its Niagara facility that was formerly part of Newstrike. HEXO destroyed the product in question.

Should you buy HEXO?

The stock trades at $3 per share at writing, giving the company a market capitalization of $760 million. That’s still high for a business with no profits and annualized revenue expectations of roughly $65 million.

The huge miss on the revenue guidance means that HEXO has a credibility issue, which is likely why the CEO and board members had to provide it with a $70 million lifeline. Given the uncertain state of its cash flow, I wouldn’t back up the truck right now.

However, contrarian investors who are bullish on the sector might want to consider a small position. Those who bought the stock near $2.25 in November have picked up a nice gain, and there could be more upside with Ontario announcing plans to allow a large increase in the number of cannabis stores in the coming year.

In addition, it wouldn’t be surprising to see HEXO acquired in the near term. Whether or not investors would receive a premium is anyone’s guess.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends HEXO. Fool contributor Andrew Walker has no position in any stock mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »